Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4)

U

University Hospital, Gentofte, Copenhagen

Status

Completed

Conditions

Glucose Metabolism Disorders

Treatments

Other: Placebo
Other: GIP-A + Exendin[9-39]
Other: GLP-1 receptor antagonist Exendin[9-39]
Other: GIP-A

Study type

Interventional

Funder types

Other

Identifiers

NCT03013296
UHG-CFD-GIPANTA-4

Details and patient eligibility

About

Delinieation of GIP's effects during a meal in humans using GIP receptor antagonisation.

Full description

Aim: To evaluate the role of GIPR signalling in postprandial physiology, including lipid, bone and glucose homeostasis, using a naturally occurring GIP fragment, which antagonises the GIPR. Twelve healthy men (age 18-70 years, BMI 19-27 kg/m2) with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised, double-blinded, placebo-controlled cross-over study. Study consists of four study days with concomitant infusions of A) GIP-A, B) GLP-1 receptor antagonist Exendin[9-39], C) GIP-A + Exendin[9-39], or D) saline (placebo).

Enrollment

12 patients

Sex

Male

Ages

18 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Normal kidney function, liver function and hemoglobin levels.

Exclusion criteria

Medication, Diabetes type 1 or 2, BMI > 27, first degree relatives with Type 2 Diabetes

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

12 participants in 4 patient groups, including a placebo group

Placebo
Placebo Comparator group
Description:
Saline
Treatment:
Other: Placebo
GIP-A
Other group
Description:
Infusion of GIP-A alone as study tool.
Treatment:
Other: GIP-A
GLP-1 receptor antagonist Exendin[9-39]
Other group
Description:
Infusion of GLP-1 receptor antagonist Exendin[9-39] alone as study tool.
Treatment:
Other: GLP-1 receptor antagonist Exendin[9-39]
GIP-A + Exendin[9-39]
Other group
Description:
Infusion of GIP-A + GLP-1 receptor antagonist Exendin[9-39] together as study tools.
Treatment:
Other: GIP-A + Exendin[9-39]

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems